MAP3K6 and prostate carcinoma: Our analysis associated low expression of MAP3K6 with better progression-free survival thus suggesting other than the tumor suppressor role for MAP3K6 in PCa and that MAP3K6 inhibition could suppress tumor growth also in prostate cancer.